Leerink Swann restated their outperform rating on shares of Neovasc Inc (US) (NASDAQ:NVCN) in a report issued on Thursday morning.

Other equities research analysts have also recently issued reports about the stock. Zacks Investment Research raised shares of Neovasc Inc (US) from a sell rating to a hold rating in a research note on Thursday, January 12th. Ladenburg Thalmann Financial Services reiterated a neutral rating on shares of Neovasc Inc (US) in a report on Wednesday, December 7th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $6.50.

Shares of Neovasc Inc (NASDAQ:NVCN) traded down 1.3550% during mid-day trading on Thursday, reaching $1.6671. 201,284 shares of the company’s stock traded hands. Neovasc Inc has a 12-month low of $0.37 and a 12-month high of $3.50. The company’s market cap is $131.20 million. The company’s 50 day moving average is $1.57 and its 200 day moving average is $1.28.

TRADEMARK VIOLATION NOTICE: “Neovasc Inc (US) (NVCN) Rating Reiterated by Leerink Swann” was first reported by Marea Informative and is the property of of Marea Informative. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at http://www.mareainformativa.com/neovasc-inc-us-nvcn-calificacion-de-acciones-reafirmado-por-leerink-swann/108313/.

A hedge fund recently bought a new stake in Neovasc Inc (US) stock. West Family Investments Inc. purchased a new stake in shares of Neovasc Inc (US) (NASDAQ:NVCN) during the fourth quarter, according to its most recent filing with the SEC. The fund purchased 2,000,000 shares of the medical equipment provider’s stock, valued at approximately $3,460,000. West Family Investments Inc. owned 2.99% of Neovasc Inc (US) as of its most recent filing with the SEC. 18.28% of the stock is owned by hedge funds and other institutional investors.

About Neovasc Inc (US)

Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.

5 Day Chart for NASDAQ:NVCN

Receive News & Stock Ratings for Neovasc Inc (US) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc (US) and related stocks with our FREE daily email newsletter.